Evidence map›Paper›PMID 33419219›Full record

ArticleInternational journal of molecular sciences2021

Conditioned Medium from Human Amnion-Derived Mesenchymal Stromal/Stem Cells Attenuating the Effects of Cold Ischemia-Reperfusion Injury in an In Vitro Model Using Human Alveolar Epithelial Cells.

Vitale Miceli, Alessandro Bertani, Cinzia Maria Chinnici, Matteo Bulati, Mariangela Pampalone, Giandomenico Amico, Claudia Carcione, Eva Schmelzer, Jörg C Gerlach, Pier Giulio Conaldi

Open access · goldAbstract read
In one paragraph

Article in International journal of molecular sciences, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
21citing papers in PubMed, 1 pooled it
5.4field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

21 citing papers in PubMed, 1 synthesis or guideline pooled it, 28 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Review
  10. Mesenchymal Stromal Cell Therapy in Lung Transplantation.Bioengineering (Basel, Switzerland) · 2023
    Review
  11. Review
  12. Review
  13. Review
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Review
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

Vitale MiceliResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), 90127 Palermo, Italy.ORCID 0000-0001-8922-9909
Alessandro BertaniThoracic Surgery and Lung Transplantation Unit, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, 90127 Palermo, Italy.
Cinzia Maria ChinniciRegenerative Medicine Unit, Fondazione Ri.MED, 90127 Palermo, Italy.ORCID 0000-0001-9318-6606
Matteo BulatiResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), 90127 Palermo, Italy.
Mariangela PampaloneRegenerative Medicine Unit, Fondazione Ri.MED, 90127 Palermo, Italy.
Giandomenico AmicoRegenerative Medicine Unit, Fondazione Ri.MED, 90127 Palermo, Italy.
Claudia CarcioneRegenerative Medicine Unit, Fondazione Ri.MED, 90127 Palermo, Italy.ORCID 0000-0002-0305-1781
Eva SchmelzerDepartment of Surgery, School of Medicine, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA 15219-3130, USA.
Jörg C GerlachDepartment of Surgery, School of Medicine, McGowan Institute for Regenerative Medicine, University of Pittsburgh, Pittsburgh, PA 15219-3130, USA.
Pier Giulio ConaldiResearch Department, IRCCS ISMETT (Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione), 90127 Palermo, Italy.
Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione · ITRi.MED · ITUniversity of Pittsburgh · US

Funding

Medical Center, University of Pittsburgh I00000171Ministero dell'Istruzione, dell'Università e della Ricerca CTN01_00177_888744
6 · The paper itself

Abstract

The clinical results of lung transplantation (LTx) are still less favorable than other solid organ transplants in both the early and long term. The fragility of the lungs limits the procurement rate and can favor the occurrence of ischemia-reperfusion injury (IRI). Ex vivo lung perfusion (EVLP) with Steen Solution

Indexed as

A549 CellsAlveolar Epithelial CellsAmnionApoptosisCell CycleCell DifferentiationCells, CulturedCell SurvivalCold IschemiaCulture Media, ConditionedCytokinesGene Expression RegulationHumansMesenchymal Stem CellsNF-kappa BReperfusion InjuryCulture Media, ConditionedCytokinesNF-kappa Bamnion-derived mesenchymal stem cellsconditioned mediumex vivo lung perfusionlung ischemia-reperfusion injury

Identifiers

PMID33419219
PMCPMC7825633
OpenAlexW3118786690

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.